Ratings MetLife, Inc. Nyse

Equities

MET.PRE

US59156R8768

Delayed Nyse 09:55:05 11/06/2024 pm IST 5-day change 1st Jan Change
23.83 USD -0.31% Intraday chart for MetLife, Inc. -0.67% -1.89%

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Its low valuation, with P/E ratio at 9.04 and 7.65 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • One of the major weak points of the company is its financial situation.

Ratings chart - Surperformance

Sector: Life & Health Insurance

1st Jan change Capi. Investor Rating ESG Refinitiv
-1.89% 49.97B -
+7.83% 76.45B
B-
+6.48% 50.23B
B
+21.28% 46.96B
B+
+10.63% 42.14B
B+
+21.64% 39.33B
B
+18.25% 34.05B
B
-1.92% 28.68B
B
-8.25% 27.44B
B-
+28.31% 26.37B
A
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes